FT-003 / Frontera - LARVOL DELTA

Interim Results for Phase I study of Intravitreal Gene Therapy FT-003 in Patients with diabetic macular edema (DME) (ARVO 2025) - P1/2 | "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Gene therapy • P1 data • Diabetic Macular Edema • Ocular Inflammation • Ophthalmology

Clinical Studies of Gene Therapy FT-003 for both Naïve and Treated nAMD via a Single Intravitreal Injection (ARVO 2025) - P1, P1/2 | "Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details."

Clinical • Gene therapy • Age-related Macular Degeneration • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Gene Therapy for DME (clinicaltrials.gov) - P1/2 | N=78 | Recruiting | Sponsor: Frontera Therapeutics

Gene therapy • New P1/2 trial • Diabetic Macular Edema • Gene Therapies • Ophthalmology

Gene Therapy(FT-003) for Wet AMD (clinicaltrials.gov) - P1/2 | N=78 | Recruiting | Sponsor: Frontera Therapeutics

Gene therapy • New P1/2 trial • Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Gene Therapy for Non-Hereditary Retinal Disease: Age-Related Macular Degeneration, Diabetic Retinopathy, and Beyond. (PubMed, Genes (Basel)) - "This manuscript reviews ongoing gene therapy clinical trials for these disorders, including ABBV-RGX-314, ixoberogene soroparvovec (ixo-vec), and 4D-150. ABBV-RGX-314 utilizes an adeno-associated virus (AAV) vector to deliver a transgene encoding a ranibizumab-like anti-VEGF antibody fragment, demonstrating promising results in Phase 1/2a and ongoing Phase 2b/3 trials...Other therapies reviewed include EXG102-031, FT-003, KH631, OLX10212, JNJ-1887, 4D-175, and OCU410. These therapies offer potential advantages of reduced treatment frequency and enhanced safety profiles, representing a paradigm shift in management towards durable and efficacious cellular-based biofactories. These advancements in gene therapy hold promise for improving outcomes in AMD and addressing the complex challenges of DME and DR, providing new avenues for the treatment of diabetic eye diseases."

Gene therapy • Journal • Review • Age-related Macular Degeneration • Diabetic Macular Edema • Diabetic Retinopathy • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration • VEGFC

Gene Therapy for Diabetic Macular Edema (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Frontera Therapeutics

Gene therapy • New P1 trial • Diabetic Macular Edema • Gene Therapies • Ophthalmology

Gene Therapy for Wet AMD (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Frontera Therapeutics | Initiation date: Nov 2022 ➔ Mar 2023

Gene therapy • Trial initiation date • Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Gene Therapy for Wet AMD (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Frontera Therapeutics

New P1 trial • Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration